Harvard spinout Platelet BioGenesis has added $26m in series A1 financing to its coffers thanks to a consortium co-led by Ziff Capital Partners and Qiming Venture Partners USA.

Platelet BioGenesis (PBG), a US-based biotechnology spinout of Harvard University, today obtained $26m in a series A1 round co-led by Ziff Capital Partners and Qiming Venture Partners USA.
Nest.Bio Ventures and eCoast Angels also contributed to the round alongside other, unnamed backers.
Founded in 2014, PBG is working on pluripotent stem-cell derived human platelets and platelet-based treatments. Platelets are a part of the bloodstream and act as a natural form of a bandaid, being responsible for clot formation…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in